FINNENCE ▪ THE WIRE FILE
THE WIRE · № 58965
News■ Unclear/unknown
Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
KINDNews
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-01 03:00 UTC
LAST UPDATE2026-10-01 03:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
CEO appointment at a clinical research firm is company-specific and has minimal broad market transmission.
Leadership change at private CRO, limited market impact
CATALYST TO WATCH
New strategic direction announcements
MAIN RISK
Transition risk and execution uncertainty
FULL DISPATCH
SINGAPORE, Oct. 1, 2026 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
←CORRELATIONshares Healthcare
Merger Dominoes Fall as HealthPartners and Essentia Combine2026-09-30 14:11 UTC
Merger Dominoes Fall as HealthPartners and Essentia Combine2026-09-30 14:11 UTC
←CORRELATIONshares Healthcare
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management2026-09-30 20:30 UTC
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management2026-09-30 20:30 UTC
←CORRELATIONshares Healthcare
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE2026-09-30 21:20 UTC
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE2026-09-30 21:20 UTC
←CORRELATIONshares Healthcare
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study2026-09-30 22:00 UTC
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study2026-09-30 22:00 UTC
←CORRELATIONshares Healthcare
FIRST-IN-HUMAN STUDY DEMONSTRATES Qi601 CAN PHYSICALLY CAPTURE MICROPLASTICS2026-09-30 23:32 UTC
FIRST-IN-HUMAN STUDY DEMONSTRATES Qi601 CAN PHYSICALLY CAPTURE MICROPLASTICS2026-09-30 23:32 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.